CJC-1295: hormone measurements and different variants
A comparison between groups of healthy young adults.
What did they want to find out?
Did the compound change growth hormone and another related measurement?
What does this example say?
The example says those measurements increased and stayed elevated.
What does this mean for you?
Hormone measurements do not prove better sports performance. The variant studied must be identified before comparing it with CJC-1295 No-DAC.
What we still do not know
We have not verified the article or the variant behind this example. A result from a DAC variant cannot automatically be transferred to a No-DAC variant. The summary also does not prove that combining it with Ipamorelin is safe or useful.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: pharmacokinetics of GHRH analogues
Journal of Clinical Endocrinology & Metabolism · 2006
How it was studied
Randomized, placebo-controlled. n = 60 healthy adults.
Original example finding
Sustained increases in GH and IGF-1 in the dose groups, according to the supplied summary.
Original example limitations
Unverified profile. Healthy young adults only; no athletic performance outcomes. Verify the variant of the compound studied.
Terms explained
- GH
- Short for growth hormone.
- IGF-1
- Another hormone-related measurement in this example.
- DAC / No-DAC
- Names that distinguish variants of the compound. They should not be treated as identical.
This link opens PubMed's search site, not a checked paper for this summary.
Open PubMed (reference unverified)